EurotransplantBank

Paris

 

EUROBANK –The “Paris group” contribution

 

 

 

The Paris group (“Laboratoire d’Immunologie et d’Histocompatibilité”, Hôpital Saint-Louis) contributed to the Eurobank project through 2 main topics :

 

 

 EBV cell line immortalisation   

 

 

h  104 Recipient/Donor Pairs have been contributed to Eurobank including:

 

o       Siblings (62), unrelated donors (40), cord blood transplants (2)

 

o       Recipient pathologies : AML (18), ALL (15), CML (21), Fanconi anemia (8), other haematological malignancies ( 20), others (22)

 

                                                             

h A continuous improvement in EBV transformation success rates has been achieved during Eurobank program:

 

 

Donor

Recipient

 

Unrelated

Sibling

Total

 

1999

73%

79%

76 %

50%

2000

75%

91%

83 %

46%

2001

92%

98%

95 %

69%

2002

89%

91%

90 %

64%

2003

96%

86%

91%

86%

 

 

h As observed by other investigators, failures of EBV transformation was found mainly in recipients affected by acute leukemias :

 

Path.

CML

AML

ALL

NHL

Fanconi

HPN

Aplasia

Others

% of failure

9%

21%

30%

14%

8%

3%

3%

12%

 

·         A special emphasis, in collaboration with the group in Newcastle (Wang et al., submitted), has been put on EBV transformations from cord blood because there is no access to donor lymphocytes in this graft setting, a small amount of DNA is available for genotyping and few cells for ethical reasons.

 

 

 

Genotyping of Eurobank cell lines  

 

 

·        Confirmatory typing (DRB1 generic typing).

·        Testing for NK KIR typing

Between February 2002 and March 2003, we have tested 230 HLA-A, B, C, DRB1, DQB1, DPB1 geno-identical BMT pairs using the following KIR markers: 2DL1, 2DL2, 2DL3, 2DS1, 2DS2, 2DS3, 2DS4, 3DL1, 3DL2, 3DS1.The impact of KIR gene incompatibility between donors and recipients and of KIR –ligand incompatibility (it means absence of the ligand in the recipient corresponding to KIR inhibitory receptor of the donor) on GvHD, survival, relapse and infection is under study.  

 

 

 

 

Publications

 

 

 

·  Clave E, Agbalika F, Bajzik V, Peffault de La Tour R, Trillard M, Rabian C, Scieux C, Devergie A, Esperou H, Ribaud P, Adès L, Gluckman E, Charron D, Socié G, Toubert A and Moins-Teisserenc H : Epstein-Barr virus (EBV) reactivation in allogeneic stem cell transplantation : relationship between viral load, EBV-specific T cell reconstitution and rituximab therapy. Transplantation, 2004;77:76-84.

 

·   Bruley Rosset M, Tieng V, Charron D and Toubert A : Differences in MHC-class I presented minor histocompatibility antigens extracted from normal and graft-versus-host disease (GVHD) mice. Clin Exp Immunol, 2003;132:46-52.

 

·   Clave E, Rocha V, Talvensaari K, Busson M, Douay C, Appert ML, Rabian C, Carmagnat MY, Garnier F, Fillion A, Gluckman E, Charron D and Toubert A : Prognostic value of pretransplant host thymic function in allogeneic hematopoietic stem cell transplantation outcomes, 30th. Annual Meeting of the European Group for Blood and Marrow Transplantation, Barcelona March 28-31, 2004 (abstract selected for oral presentation in plenary session).

 

·  Wang XN, Dickinson AM, Douglas EA, Rae M, Fournier I, Dosquet C, Charron D, Gluckman E and Toubert A : EBV-transformation of cells from cord blood donations-relevance to the future retrospective studies on cord blood transplants. Submitted.

 

·  Clave E, Rocha V, Talvensaari K, Busson M, Douay C, Appert ML, Rabian C, Carmagnat M, Garnier F, Filion A, Socie G, Gluckman E, Charron D and Toubert A : Prognostic value of pretransplant host thymic function in allogeneic hematopoietic stem cell transplantation. Submitted.